- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07232732
En studie av LY3549492 hos friske deltakere og deltakere med overvekt eller fedme
En fase-1, parallell-design, åpen merket, randomisert, multipledosiseskaleringsstudie for å undersøke sikkerhet, tolerabilitet og farmakokinetikk for LY3549492 hos friske deltakere med overvekt eller fedme
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Daytona Beach, Florida, Forente stater, 32117
- Fortrea Clinical Research Unit
-
-
Texas
-
Dallas, Texas, Forente stater, 75247
- Fortrea Clinical Research Unit
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53704
- Fortrea Clinical Research Unit
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
- Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
- Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
-
Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
-
Have any of the following conditions at screening,
- supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater
- supine diastolic blood pressure of 100 mmHg or greater, or
- resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included).
-
Have had any of the following within 6-months prior to screening
- myocardial infarction
- unstable angina
- coronary artery bypass graft
- percutaneous coronary intervention. (Note: diagnostic angiograms are permitted)
- transient ischemic attack
- cerebrovascular accident or decompensated congestive heart failure, or
- New York Health Association Class III or IV heart failure.
-
Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter [mg/dL]) at screening
-
Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LY3549492 (Treatment Group 1)
LY3549492 administered orally. |
Administered orally |
|
Eksperimentell: LY3549492 (Treatment Group 2)
LY3549492 administered orally. |
Administered orally |
|
Eksperimentell: LY3549492 (Treatment Group 3)
LY3549492 administered orally. |
Administered orally |
|
Eksperimentell: LY3549492 (Treatment Group 4)
LY3549492 administered orally. |
Administered orally |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Tidsramme: Baseline through end of the Follow-up Period (Week 10)
|
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module |
Baseline through end of the Follow-up Period (Week 10)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3549492
Tidsramme: Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: Cmax of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
|
PK: Observed Drug Trough Concentration (Ctrough) of LY3549492
Tidsramme: Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: Ctrough of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
|
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3549492
Tidsramme: Predose on Day 1 through end of the Follow-up Period (Week 10)
|
PK: AUC of LY3549492 |
Predose on Day 1 through end of the Follow-up Period (Week 10)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 27786
- J3H-MC-GZNJ (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .